Genetic Technologies Completes $12.7M Private Placement

The funds, raised through a private placement of 60 million shares at A$.195 per share will be used to fund "acquisition growth" and the roll-out of its BrevaGen test in the US.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.